可溶性ST2和半乳糖凝集素3在心力衰竭中的应用进展  

Research advance in the application of soluble suppression of tumorigenicity 2 and galectin-3 in heart failure

作　　者：保永宏 马一铭 蔡红雁[1] Bao Yonghong;Ma Yiming;Cai Hongyan(Department of Cardiology,the First Affiliated Hospital of Kunming Medical University,Kunming 650032,China)

机构地区：[1]昆明医科大学第一附属医院心内科,650032

出　　处：《中国心血管杂志》2018年第5期425-428,共4页Chinese Journal of Cardiovascular Medicine

基　　金：云南省医学学科带头人培养项目(D-201622)~~

摘　　要：心力衰竭是各种心脏疾病的终末阶段。近年来对心力衰竭的诊治水平取得了较大的提高,但心力衰竭的患病率和死亡率仍处于一个较高水平。目前心力衰竭仍是心血管疾病导致死亡的最主要的因素之一,已成为主要公共卫生问题。生物标记物能反映心力衰竭的不同病理生理过程,对帮助诊断或鉴别诊断心力衰竭、判断预后及危险分层和指导治疗等具有重要的临床应用前景。本文就新型生物标记物可溶性人基质裂解素2和半乳糖凝集素3在心力衰竭中的应用现状进行综述。Heart failure is the end stage of various heart diseases.Although the development of diagnosis and treatment on heart failure in recent years has been greatly improved,the prevalence and mortality of heart failure are still high.Heart failure is still one of the most important factors in the death of cardiovascular disease,which has become a major public health problem.Biomarkers can reflect the different pathophysiological processes of heart failure,and is helpful for diagnosis,or differential diagnosis of heart failure,prognosis and risk stratification,and treatment.Research advances of soluble suppression of tumorigenicity 2 and galectin-3 were reviewed in this article.

关 键 词：可溶性人基质裂解素2 半乳糖凝集素3 生物学标记 心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]